{"id":6826,"date":"2024-10-03T07:30:22","date_gmt":"2024-10-03T11:30:22","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2024-10-02T16:00:18","modified_gmt":"2024-10-02T20:00:18","slug":"bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/","title":{"rendered":"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions"},"content":{"rendered":"<p align=\"left\"><strong>PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE)<\/strong> &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 \u2013 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.<\/p>\n<p><strong><u>Featured Science Oral Presentation:<\/u><\/strong><br \/>\n<strong>Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study<\/strong><br \/>\n<strong>Session Title:<\/strong>\u00a0Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations<br \/>\n<strong>Presenter:<\/strong>\u00a0Daniel Judge, M.D. of Medical University of South Carolina<br \/>\n<strong>Date:<\/strong>\u00a0Monday, November 18 at 9:45 am CT\/10:45 am ET<\/p>\n<p><strong><u>Moderated Digital Posters:<\/u><\/strong><br \/>\n<strong>Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Generalized Heart Failure<\/strong><br \/>\n<strong>Session Title:<\/strong>\u00a0Socioeconomic Insights and Innovations in Heart Failure<br \/>\n<strong>Presenter:<\/strong>\u00a0Justin\u00a0Grodin, M.D. of UT Southwestern Medical Center<br \/>\n<strong>Date:<\/strong>\u00a0Sunday, November 17 at 10:00 am CT\/11:00 am ET<\/p>\n<p><strong>Evolving Baseline Risk in Patients with Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials<\/strong><br \/>\n<strong>Session Title:\u00a0<\/strong>Cardiac Amyloidosis 2024: Advances in Prognostication and Management<br \/>\n<strong>Presenter:<\/strong>\u00a0Ahmad Masri, M.D. of Oregon Health &amp; Science University<br \/>\n<strong>Date:<\/strong>\u00a0Sunday, November 17 at 11:10 am CT\/12:10 pm ET<\/p>\n<p><strong>Acoramidis Improved Survival in Patients with Transthyretin Cardiac Amyloidosis Regardless of Prior Cardiovascular Hospitalization<\/strong><br \/>\n<strong>Session Title:<\/strong>\u00a0Cardiac Amyloidosis 2024: Advances in Prognostication and Management<br \/>\n<strong>Presenter:<\/strong>\u00a0Kevin Alexander, M.D. of Stanford University School of Medicine<br \/>\n<strong>Date:<\/strong>\u00a0Sunday, November 17 at 11:20 am CT\/12:20 pm ET<\/p>\n<p>The presentation and posters will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at\u00a0<a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>https:\/\/investor.bridgebiodev.wpengine.com<\/strong><\/a>.<\/p>\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><br \/>\nBridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u00a0<a href=\"http:\/\/bridgebio.com\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/6824982\/admin\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>LinkedIn<\/strong><\/a>,\u00a0<a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"nofollow noopener\"><strong>Twitter<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.facebook.com\/profile.php?id=61561087329761\" target=\"_blank\" rel=\"nofollow noopener\"><strong>Facebook<\/strong><\/a>.<\/p>\n<p><strong>BridgeBio Contact:<\/strong><br \/>\nVikram Bali<br \/>\n<a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\"><strong>contact@bridgebiodev.wpengine.com<\/strong><\/a><a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n<\/a>(650)-789-8220<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8,10],"tags":[],"class_list":["post-6826","post","type-post","status-publish","format-standard","hentry","category-news","category-press-release"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-03T11:30:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-02T20:00:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Holly Condon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Holly Condon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/\",\"name\":\"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2024-10-03T11:30:22+00:00\",\"dateModified\":\"2024-10-02T20:00:18+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96\",\"name\":\"Holly Condon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g\",\"caption\":\"Holly Condon\"},\"url\":\"https:\/\/bridgebio.com\/author\/holly-condonbridgebio-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio","og_description":"PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/","og_site_name":"BridgeBio","article_published_time":"2024-10-03T11:30:22+00:00","article_modified_time":"2024-10-02T20:00:18+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Holly Condon","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Holly Condon","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/","name":"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2024-10-03T11:30:22+00:00","dateModified":"2024-10-02T20:00:18+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attribute-cm-the-phase-3-study-of-acoramidis-for-treatment-of-attr-cm-at-2024-aha-scientific-sessions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/4add0b7d61d0ea7518a9f18377b57f96","name":"Holly Condon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32160078eac50cc259c3cf6057162339?s=96&d=mm&r=g","caption":"Holly Condon"},"url":"https:\/\/bridgebio.com\/author\/holly-condonbridgebio-com\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6826"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6826"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6826\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=6826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=6826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}